Introduction
The BCR-ABL fusion oncogene is responsible for the pathogenesis of chronic myelogenous leukemia (CML) (Quintas-Cardama and Cortes, 2009) , which is characterized by the premature release of myeloid cells from bone marrow as well as a substantial accumulation of myeloid cells in the blood, spleen and bone marrow. Owing to its elevated tyrosine kinase activity, BCR-ABL activates a number of signaling pathways, including the Ras, phosphatidylinositol 3-kinase/Akt, Janus kinase/ signal transducer and activator of transcription (STAT) and nuclear factor-kB signaling pathways (Ren, 2005; Quintas-Cardama and Cortes, 2009 ). Moreover, in various human and mouse models, hematopoietic cells expressing BCR-ABL show a growth advantage, resistance to apoptosis and altered adhesion and homing properties. In clinical research, tyrosine kinase inhibitors targeting BCR-ABL have dramatically improved the therapeutic outcomes of patients with CML (Gorre et al., 2001; Shah et al., 2002; Corbin et al., 2003; Gambacorti-Passerini et al., 2003b; Lowenberg, 2003; Hochhaus and La Rosee, 2004) . For instance, the agent imatinib mesylate led to a large number of cytogenic and molecular responses in CML patients, resulting in greatly prolonged survival. However, a considerable proportion of these patients exhibited either primary or secondary resistance, or intolerance to imatinib (Cortes et al., 2007) . In addition, in a multicenter, nonrandomized Stop Imatinib trial, B60% of the patients relapsed after an interruption to the imatinib therapy, although they had maintained a complete molecular response (Mahon et al., 2010) . Thus, additional strategies to completely eliminate CML cells, especially leukemic stem cells, are necessary.
Signal-transducing adaptor protein-2 (STAP-2) is a novel adaptor molecule, which was isolated as a c-fmsinteracting protein . The human homolog of STAP-2 is a known substrate of the breast tumor kinase (Mitchell et al., 2000) . Structurally, STAP-2 contains a pleckstrin homology (PH) domain in the Nterminal region and a region distantly related to the Src homology 2 (SH2) in the central region. Its C-terminal region also has a proline-rich region and an YXXQ motif . Previous works in this laboratory found that STAP-2 have the ability to associate with and influence a variety of signaling or transcriptional molecules Yamamoto et al., 2003; Sekine et al., 2005 Sekine et al., , 2006 Sekine et al., , 2007b Sekine et al., , 2009a , including the finding that STAP-2 can modulate the transcriptional activity of STAT3 and STAT5 Sekine et al., 2005) , in addition to the FceRI and Toll-like receptor-mediated signals Sekine et al., 2006) . Furthermore, thymocytes and peripheral T cells from STAP-2-deficient mice show enhanced interleukin-2 (IL-2)-or T cell receptor-dependent cell growth, integrin-mediated T-cell adhesion and impaired stromal cell-derived factor-1a (SDF-1a)-induced T-cell migration (Sekine et al., 2005 (Sekine et al., , 2007b (Sekine et al., , 2009a . Because STAP-2 is expressed in a variety of tissues and cells, such as lymphocytes, macrophages and hepatocytes, STAP-2 is also likely to function in a variety of different cells.
In this study, we identified BCR-ABL, in addition to BCR and ABL as novel binding partners of STAP-2. In the presence of STAP-2, BCR-ABL was highly phosphorylated. In parallel, the associated downstream signals were also enhanced. We also found that STAP-2 overexpression in murine hematopoietic cells confers a growth advantage in vitro and is able to induce leukemia in vivo. Furthermore, STAP-2 knockdown in K562 CML cells fails to form tumors in vivo. In addition, STAP-2 controls the migration and homing of BCR-ABL-expressing cells by influencing chemokine receptor expression levels. Therefore, STAP-2 is required for the full activity of BCR-ABL.
Results

STAP-2 binds to BCR-ABL in addition to BCR and ABL proteins
To fully identify the STAP-2 interacting proteins, we used a yeast two-hybrid system to screen a mouse embryo complementary DNA (cDNA) library using human STAP-2 (amino acids 1-403) as the bait. From a total population of B2.6 Â 10 6 transformants, we isolated several positive clones. Sequence analysis revealed that one encoded the C-terminal region of BCR (amino acids 880-1270). We then examined whether STAP-2 binds to BCR in mammalian cells. A series of 293T cells were transfected with glutathione S-transferase (GST)-tagged STAP-2 expression vectors together with Myc-tagged BCR (amino acids 880-1270). The specific binding was examined via pull-down assays with glutathione-sepharose, followed by western blot analysis with an anti-Myc or anti-GST antibody. The GST-STAP-2 protein precipitates clearly contained the BCR protein (Figure 1a ), indicating that STAP-2 directly interacts with BCR in 293T cells. Because the BCR fragment in part overlapped with the BCRABLp210 chimera protein sequence (Pendergast et al., 1991; Ren, 2005; Quintas-Cardama and Cortes, 2009 ), we also investigated whether STAP-2 interacts with the BCR-ABL oncoprotein. We then transfected the 293T cells with expression vectors encoding BCR-ABL (p210 or p190) and Myc-tagged STAP-2. The transfectants were then lysed and subjected to immunoprecipitation with an anti-Myc antibody. The immunoprecipitates were then run on a western blot with an anti-ABL antibody. As shown in Figure 1b , STAP-2 bound to both BCR-ABL p210 and p190. The binding between STAP-2 and BCR-ABLp190 was unexpected because BCR-ABLp190 is composed of BCR (amino acids 1-426). This finding raised the possibility that STAP-2 may recognize not only BCR but also ABL. Thus, we investigated whether STAP-2 interacts with the ABL protein. We transfected the 293T cells with the Myctagged STAP-2 and His-tagged ABL and the transfectants were then lysed and subjected to immunoprecipitation with an anti-ABL antibody. The precipitates for ABL contained the STAP-2 proteins (Figure 1c ), indicating that STAP-2 directly interacts with ABL. To further detect a physical interaction between STAP-2 and BCR-ABL in the CML cells, co-immunoprecipitation experiments were performed using a CML cell line K562, which constitutively expresses STAP-2. As shown in Figure 1d , we were able to demonstrate a direct interaction between STAP-2 and BCR-ABL at endogenous levels through the detection of BCR-ABL in K562 cells after immunoprecipitation with a human STAP-2 antibody. Therefore, STAP-2 interacts with BCR-ABL as well as the BCR and ABL proteins. We further examined whether the interaction between STAP-2 and BCR-ABL depends on BCR-ABL phosphorylation. To this end, we first investigate the effect of BCR-ABL phosphorylation in the Ba/F3 transfectants by treatment with STI571. Treatment with STI571 resulted in a marked decrease of BCR-ABL phosphorylation in the Ba/F3 transfectants (p210 and p210/ STAP-2 no. 1) (Supplementary Figure 1a) . We next tested the effect of treatment with STI571 on the interaction between STAP-2 and BCR-ABL. We then transfected the 293T cells with expression vectors encoding BCR-ABL (p210) and Myc-tagged STAP-2. The transfectants were treated or untreated with STI571, and then lysed and subjected to immunoprecipitation with an anti-Myc antibody. The immunoprecipitates were then run on a western blot with an anti-ABL antibody. Treatment with STI571 reduced the complex formation between STAP-2 and BCR-ABL p210 (Supplementary Figure 1b) .
STAP-2 enhances BCR-ABL activity
To examine the effect of STAP-2 on the function of BCR-ABL, we stably transfected a STAP-2 expression vector into Ba/F3 cells expressing BCR-ABL (Ba/F3-p210). Western blot was used to confirm STAP-2 and BCR-ABL protein expression in the two clones (STAP-2 wild-type (WT) no. 1 and 2; see Figure 2c ). Both STAP-2 WT no. 1 and 2 showed markedly enhanced BCR-ABL-dependent cell growth and resistance to a BCR-ABL inhibitor, STI571 (Figures 2a and b) . This finding suggests that STAP-2 positively regulates the BCR-ABL-dependent Ba/F3 cell growth. To investigate the molecular mechanisms underlying this process, we first examined tyrosine phosphorylation in the Ba/F3 transfectants. As shown in Figure 2c , intracellular tyrosine Activation of downstream signaling molecules including ERK (extracellular-signal-regulated kinase), STAT5, BCL-xL (B-cell lymphoma-extra large) or BCL-2 (B-cell lymphoma 2) was also enhanced in the STAP-2 WT no. 1 and 2 cells (Figure 2c ). Furthermore, cell cycle analysis with flow cytometry showed that STAP-2 overexpression significantly suppressed the appearance cells at the sub-G1 phase 24 h after the depletion of IL-3 (Figure 2f ), indicating that in these cells STAP-2 also augments the inhibition of apoptosis induced by BCR-ABL. Therefore, STAP-2-enhanced BCR-ABL phosphorylation results in a growth advantage and enhanced cell survival. To clarify the role of endogenous STAP-2 and BCR-ABL, we used a CML cell line K562, which constitutively expresses STAP-2. We first established a STAP-2-knockdown variant of the K562 cells using short hairpin RNA (shRNA; K562 STAP-2 shRNA no. 1 and 2), in which the STAP-2 expression was confirmed with quantitative real-time PCR analysis (Figure 3a) . Our findings revealed that cell proliferation in the K562 STAP-2 shRNA no. 1 and 2 cells was slower than in the control K562 cells (Figure 3b ). In addition, the STAP-2-knockdown clones were more sensitive to STI571 than the controls (Figure 3c ). When tyrosine phosphorylation was examined in the STAP-2 shRNA cells, a decrease in tyrosine phosphorylation in the cytoplasm was also observed (Figure 3d ). We could see some alteration in pTyr bands with molecular weight of B100 kDa. Furthermore, the phosphorylation status of the BCR-ABL downstream signaling molecule, STAT5b, was also diminished (Figure 3e ). We then analyzed the effects of STAP-2 knockdown on tyrosine phosphorylation of STAT5 as well as CBL and VAV whose molecular weight is B100 kDa and their activation by BCR-ABL was already reported (Brehme et al., 2009; Chang et al., 2009) . As shown in Figure 3f , tyrosine phosphorylation of both CBL and VAV also reduced in STAP-2-knockdown K562 cells. We also tested the mRNA expression of STAT5b, BCL-2, BCL-xL and CYCLIN D1 in the STAP-2-knockdown K562 cells (shSTAP-2 no. 1 and 2). As shown in Figure 3g , the mRNA expression of these proteins was significantly downregulated in STAP-2-knockdown cells as compared with the vector control cells (shControl no. 1 and 2). Therefore, at the physiological levels, interactions between STAP-2 and BCR-ABL play a crucial role in the control of BCR-ABL activity.
The SH2 domain of STAP-2 binds to BCR-ABL To determine the STAP-2 domains involved in its association with BCR-ABL, a series of STAP-2 deletion mutants fused with GST (GST-STAP-2 PH, GST-STAP-2 SH2 and GST-STAP-2 C) were examined ( Figure 4a ). The respective mutants, together with BCR-ABL, were transiently expressed in 293T cells. The binding potential of these proteins with BCR-ABL were examined by pull-down assays with glutathionesepharose, followed by western blot analysis with anti-ABL or anti-GST antibodies. The precipitates for the GST-STAP-2 WT and GST-STAP-2 SH2 protein contained the BCR-ABL protein (Figure 4b ). Therefore, ) and K562-shSTAP-2 (no. 1and 2) cells were established. Total RNA samples isolated from these cells were also quantified by reverse transcription and quantitative real-time PCR analysis. Data represent the levels of these mRNA normalized to that of an ACTIN internal control and are expressed relative to the value of control shRNA-treated samples. Shown is a representative experiment, which was repeated at least three times with similar results. (b) K562-shControl (no. 1 and 2) and K562-shSTAP-2 (no. 1and 2) cells (5 Â 10 3 cells/well) in 96-well plates were cultured for the indicated periods. Cell growth was measured using a Cell Counting Kit-8. The data are the means of triplicate experiments, which generally varied by o10%. Similar results were obtained in three independent experiments. **Po0.01 and ***Po0.001 indicate significant difference (vs K562-shControl no. 1). (c) K562-shControl (no. 1 and 2) and K562-shSTAP-2 (no. 1and 2) cells (2 Â 10 4 cells/ well) in 96-well plates were cultured in the presence of STI571 (0, 3, 5 and 10 mM) in 96-well plates for 24 h. Cell growth was measured using a Cell Counting Kit-8. The data are the means of triplicate experiments, which generally varied by o10%. Similar results were obtained in three independent experiments. *Po0.05 and **Po0.01 indicate significant difference (vs K562-shControl no. 1). (d, e) K562-shControl (no. 1 and 2) and K562-shSTAP-2 (no. 1and 2) cells (1 Â 10 6 cells/well) in 12-well plates were cultured for 24 h. The cells were lysed, and immunoblotted with anti-PY described in (d), anti-pSTAT5, anti-STAT5b, anti-PY, anti-ABL, anti-pERK, anti-ERK, anti-BCL-xL and anti-Actin antibody described in (e). (f) K562-shControl (no. 1 and 2) and K562-shSTAP-2 (no. 1 and 2) cells (5 Â 10 6 cells) cells were lysed, and immunoprecipitated with anti-CBL (upper panels) or anti-VAV antibody (lower panels) and blotted with anti-PY, anti-CBL or anti-VAV antibody. An aliquot of total cell lysate (TCL) was also blotted with anti-CBL or anti-VAV antibody. (g) Total RNA samples isolated from K562-shControl (no. 1 and 2) and K562-shSTAP-2 (no. 1 and 2) cells were subjected to quantitative real-time PCR analysis using STAT5b, BCL-2, BCL-xL, CYCLIN D1 and G3PDH primers. *Po0.05, **Po0.01 and ***Po0.001 indicate significant difference.
Functional interactions between STAP-2 and BCR-ABL
Y Sekine et al BCR-ABL phosphorylates STAP-2 at the position of Tyr250 STAP-2 has four tyrosine residues. To determine the phosphorylation status of these residues, we examined tyrosine phosphorylation of STAP-2 using BCR-ABL. The Myc-tagged STAP-2 was expressed without or with BCR-ABL in 293T cells. The cells were lysed, and the lysates were probed with anti-phosphotyrosine (PY), anti-Myc or anti-ABL antibodies. As shown in Figures   5a and b, a significant degree of tyrosine phosphorylation of STAP-2 by BCR-ABLp190 and p210 was observed. We also utilized a series of STAP-2 YF mutants in which four potential tyrosine phosphorylation sites were mutated to phenylalanine (Figure 5c ). To further probe the phosphorylation status of STAP-2 Tyr250, we also used a phospho-specific antibody against the Tyr250 site, designated anti-pSTAP-2 Tyr250, as described previously (Sekine et al., 2007a) . ) were transfected with p210BCR-ABL (10 mg) with or without GST-fused STAP-2 mutants (8 mg). At 48 h after transfection, the cells were lysed, and pulled down with GSH-Sepharose and immunoblotted with an anti-PY, anti-ABL and anti-GST antibody. An aliquot of each total cell lysate (TCL) was immunoblotted with anti-PY or anti-ABL antibody. (c) Ba/F3-p210, Ba/F3-p210/STAP-2no. 2 and Ba/F3-p210/STAP-2 DSH2 (no. 1 and 2) cells (3 Â 10 3 cells/well) in 96-well plates were cultured without IL-3 (WEHI-3B conditioned medium) for the indicated periods. Cell growth was using a Cell Counting Kit-8. The data are the means of triplicate experiments, which generally varied by o10%. Similar results were obtained in three independent experiments. ***Po0.001 indicates significant difference (vs Ba/F3-p210/STAP-2 WT no. 2). (d) Ba/F3-p210, Ba/F3-p210/STAP-2 no. 2 and Ba/F3-p210/STAP-2 DSH2 (no. 1 and 2) cells (2 Â 10 4 cells/well) in 96-well plates were cultured without IL-3 (WEHI-3B conditioned medium) in the presence of STI571 (0, 1, 3 and 5 mM) for 24 h. The cell numbers were measured using a Cell Counting Kit-8. The data are the means of triplicate experiments, which generally varied by o10%. Similar results were obtained in three independent experiments. **Po0.01 and ***Po0.001 indicate significant difference (vs Ba/F3-p210/STAP-2 WT no. 2). (e) Ba/F3-p210, Ba/F3-p210/STAP-2 no. 2 and Ba/F3-p210/STAP-2 DSH2 (no. 1 and 2) cells (1 Â 10 6 cells/well) in 12-well plates were cultured with or without IL-3 (5% of WEHI-3B conditioned medium) for 24 h. The cells were lysed, and immunoblotted with anti-PY, anti-ABL, anti-Myc, anti-pERK, anti-ERK, anti-BCL-xL, anti-BCL-2 and anti-Actin antibody. (f) Ba/F3-p210, Ba/F3-p210/STAP-2 no. 2 and Ba/F3-p210/STAP-2 DSH2 (no. 1 and 2) cells (1 Â 10 6 cells) were cultured with or without IL-3 (5% of WEHI-3B conditioned medium) for 24 h. The cells were lysed, and immunoblotted with anti-PY, anti-ABL or anti-Myc antibody. (g) Ba/F3-p210, Ba/F3-p210/STAP-2 no. 2 and Ba/F3-p210/STAP-2 DSH2 no. 1 cells (1 Â 10 7 cells) were lysed, and immunoprecipitated with anti-Myc antibody and immunoblotted with anti-ABL or anti-Myc (upper panels). An aliquot of TCL was also blotted with anti-ABL or antiMyc antibody (lower panels).
Functional interactions between STAP-2 and BCR-ABL Y Sekine et al
The Myc-tagged WT STAP-2 (STAP-2 WT) and a series of STAP-2 YF mutants were expressed with or without BCR-ABL in the 293T cells. The STAP-2 WT and YF mutant proteins expressed in the cells were then immunoblotted using anti-pSTAP-2 Tyr250, anti-PY and anti-Myc antibodies. The STAP-2 WT and YF mutant proteins, with or without BCR-ABL coexpression, were expressed at an equivalent level. In contrast, the anti-pSTAP-2 Tyr250 or anti-PY antibody failed to recognize the STAP-2 Y250F mutant coexpressed with BCR-ABL (Figures 5d and e) . Therefore, STAP-2 Tyr250 is the major site of tyrosine phosphorylation by BCR-ABL.
The role of Tyr250 in interactions between STAP-2 and BCR-ABL
We also tested the effect of STAP-2 Tyr250 on BCR-ABL-induced cell proliferation by using Ba/F3-p210 cells overexpressing STAP-2 Y250F whose tyrosine residue at amino acid 250 was substituted to phenyla- (Figures 5f and g ), although the STAP-2 WT and Y250F expression levels were comparable (data not shown). Furthermore, tyrosine phosphorylation of a number of cellular proteins, including BCR-ABL itself, was only moderately enhanced in the STAP-2 Y250F no. 1 and 2 cells relative to the STAP-2 WT no. 2 cells (Figures 5h and i) . Therefore, tyrosine phosphorylation of STAP-2 Tyr250 is required for full enhancement of BCR-ABL activity.
BCR-ABL and BCR-ABL/STAP-2-expressing Ba/F3 cells show differing patterns of tumor progression
To investigate the effect of STAP-2 on the ability of transfected cells to induce tumor formation in vivo, we subcutaneously injected Ba/F3 transfectants into the flank of BALB/c nude mice. As shown in Figure 6a , the Ba/F3-p210 cells were lethal to the mice within 43.2 days. Importantly, lethality was augmented in the Ba/F3 cells expressing both BCR-ABL and STAP-2 (all mice died within 31 days). Mice injected with the vector control cells had no evidence of disease for at least 90 days. These results indicate that STAP-2 enhances BCR-ABL-mediated tumor progression in vivo. Mice injected with BCR-ABL-expressing Ba/F3 cells formed large tumors at the injection site (Figures 6b and c) . However, these mice developed only small lymph node and spleen swelling (Figure 6d) . Surprisingly, mice injected with BCR-ABL/STAP-2-expressing Ba/F3 cells developed small tumors at the injection sites but substantial lymph node swelling and hepatosplenomegaly (Figures 6b-d) .
The difference in tumor progression was also confirmed by the variable tumor weights observed between the groups (Figure 6e ). In addition, the livers harvested from the mice injected with BCR-ABL/STAP-2-expressing but not BCR-ABL-expressing Ba/F3 cells showed a (Figure 6f ). Therefore, STAP-2 influences the migration and homing of BCR-ABL-expressing Ba/F3 cells.
Suppression of STAP-2 in K562 CML cells fails to form tumors in vivo
To further investigate the effect of STAP-2 in K562 CML cells on the ability to induce tumor formation in vivo, we subcutaneously injected K562 transfectants (K562 control shRNA no. 1 and K562 STAP-2 shRNA no. 1) into the flank of BALB/c nude mice. Mice injected with K562 control shRNA no. 1 cells formed large tumors at the injection site (Figures 7a-c) , although we could not observe any metastasis in this model. Importantly, mice injected with K562 STAP-2 shRNA no. 1 cells failed to form tumors (Figures 7a-c) . The difference in tumor formation was also confirmed by the tumor weights observed between the groups (Figure 7d ). Therefore, STAP-2 influences tumor formation of K562 CML cells.
STAP-2 cooperates with BCR-ABL to modify the expression of chemokine receptors
We previously showed that STAP-2 regulates SDF-1a-induced T-cell migration via activation of Vav1/Rac1 signaling, suggesting that STAP-2 may be involved in chemokine functions (Sekine et al., 2009a) . To clarify the tumor progression between BCR-ABL/STAP-2 and BCR-ABL-expressing Ba/F3 cells, we examined the mRNA expression levels of a series of chemokine receptors in the Ba/F3 transfectants. The mRNA expression of CCR1, CCR7 and CXCR1 was higher in the BCR-ABL/STAP-2-expressing Ba/F3 cells than in the BCR-ABL-expressing Ba/F3 cells (Figure 8a ). In contrast, mRNA expression of CXCR4 was downregulated by STAP-2 (Figure 8a ). We also tested the mRNA expression of these chemokine receptors in the STAP-2-knockdown K562 cells (shSTAP-2 no. 1 and 2). As shown in Figure 8b , the mRNA expression of CCR1 and CCR7 was downregulated in STAP-2-knockdown cells as compared with the vector control cells (shControl no. 1 and 2), whereas mRNA expression levels of CXCR4 were strongly upregulated in the STAP-2-knockdown K562 cells as compared with the vector control cells. However, the mRNA expression of CXCR1 was not altered in these cells. We next examined the effect of STAP-2 on SDF-1a-induced Ba/F3 migration. As shown in Figure 8c , there was a reduction in migration in the BCR-ABL-expressing Ba/F3 cells in response to SDF-1a, although spontaneous migration was slightly enhanced in the BCR-ABL-expressing 
Discussion
In this study we demonstrated that STAP-2 interacts with and modifies the function of various signaling or transcription molecules Yamamoto et al., 2003; Sekine et al., 2005 Sekine et al., , 2006 Sekine et al., , 2007b Sekine et al., , 2009a . We also demonstrated that BCR-ABL acts as a novel binding partner for STAP-2 in the presence of both the STAP-2 SH2-like domain and STAP-2 Tyr250 phosphorylation. Importantly, STAP-2 SH2-like domain is required for physical and functional interactions between STAP-2 and BCR-ABL. The interaction between STAP-2 and BCR-ABL led to increased BCR-ABL phosphorylation status. Moreover, there was also an effect on downstream signaling, resulting in the enhanced cell proliferation and the altered chemokine receptor expression. An important finding of this study was that STAP-2 cooperates with BCR-ABL to change tumor progression patterns in mice injected with transfected Ba/F3 cells. Furthermore, suppression of STAP-2 in human K562 CML cells resulted in no tumor formation in mice. Therefore, STAP-2 is likely to be involved in the pathogenesis of CML. In general, BCR-ABL activates multiple signaling pathways, which induce cell growth and survival (Ren, 2005; Quintas-Cardama and Cortes, 2009) . The RAS/ mitogen-activated protein kinase pathway is activated, leading to the induction of BCL-2 transcription. The phosphatidylinositol 3-kinase/AKT pathway is also activated and mediates a network of targets, including FOXO proteins, Bad and glycogen synthase kinase-3b (Datta et al., 1997; del Peso et al., 1997; Pap and Cooper, 1998; Brunet et al., 1999) . This BCR-ABLdependent phosphatidylinositol 3-kinase activation is in part mediated by GAB2 and/or c-CBL (Sattler et al., 1996; Chu et al., 2007) . Furthermore, STAT5, which regulates CYCLIN D1 and BCL-xL, is activated by BCR-ABL independent of Jak family proteins (Xie et al., 2001) . STAT5a/b-deficient fetal liver hematopoietic progenitors fail to generate leukemia in recipient mice after retroviral transduction with BCR-ABL (Hoelbl et al., 2006) . Among these BCR-ABL-related signaling molecules, we previously found that STAP-2 binds to and regulates c-CBL and STAT5 (Sekine et al., 2005 (Sekine et al., , 2009b . In particular, in a breast cancer model, STAP-2 was found to greatly enhance BRK-mediated STAT5 activation (Sekine et al., 2007b; Ikeda et al., 2011) . Therefore, in addition to increased BCR-ABL phosphorylation, STAP-2 is likely to be involved in multiple events downstream of BCR-ABL. In this study, BCR-ABL-mediated expression of BCL-2 and BCL-xL was largely depending on the level of STAP-2. Manipulation of STAP-2 expression altered phosphorylation state of various signaling molecules. Among them, ERK phosphorylation well correlated with expression levels of BCL-2 and BCL-xL. Because the BCR-ABL/Ras pathway is one of the major signals, the two antiapoptotic molecules may be controlled by STAP-2 in BCR-ABL-positive cells. Alternatively, STAT5, another signaling molecule to drive expression of BCL-2 and BCL-xL, may also participate in this process. We showed that STAT5 expression level was influenced by the interaction between BCR-ABL and STAP-2.
Resistance to imatinib in CML patients has been related to changes to BCR-ABL-dependent or -independent mechanisms (Quintas-Cardama and Cortes, The most frequent process underlying this mechanism is point mutations to BCR-ABL involving the ATP-binding pocket, which prevent imatinib binding (Hughes et al., 2006; O'Hare et al., 2007) . However, other mechanisms have also been implicated including the duplication and amplification of the BCR-ABL (Weisberg and Griffin, 2000; le Coutre et al., 2000) . Imatinib export via the p-glycoprotein efflux pump (Mahon et al., 2000) , reduced expression of the organic cation transporter OCT1 (Crossman et al., 2005; Wang et al., 2008) , binding of imatinib to the plasma by a1-acid glycoprotein (Gambacorti-Passerini et al., 2003a) and the activation of alternative signaling cascades leading to BCR-ABL-independent growth (Donato et al., 2003; Ptasznik et al., 2004) . With regard to STAP-2 expression, one gene expression database on CML patient samples reported that STAP-2 was expressed by CD34 þ cells (D Bruennert, 2009) . Our data also indicate that STAP-2 plays a role in acquiring resistance to imatinib through alternative pathways, including enhancing BCR-ABL activity. A putative mechanism is that binding of STAP-2 induces conformational change of BCR-ABL, increasing its affinity to ATP. Another potential mechanism is that STAP-2 modifies the interaction between BCR-ABL and imatinib. However, further analysis is required to clarify the relationship between STAP-2, BCR-ABL and imatinib, and the potential to utilize STAP-2 expression in the prediction of imatinib sensitivity.
The CXCR4 chemokine receptor belongs to a family of seven transmembrane-spanning proteins. The natural ligand for CXCR4 is SDF-1a, a CXC chemokine constitutively produced by bone marrow stromal cells. Inhibition of CXCR4 function via blocking antibodies results in a considerable delay in bone marrow engraftment by human hematopoietic stem cells into NOD-SCID mice (Peled et al., 1999) , coupled with the appearance of CXCR4-deficient hematopoietic progenitors in the circulation (Ma et al., 1999) . Thus, the expression of CXCR4 on hematopoietic stem/progenitor cells is involved in their homing and retention in bone marrow. Several studies have reported cross-talk between BCR-ABL and CXCR4. In hematopoietic cell lines, overexpression of BCR-ABL revealed impaired migration and signaling in response to SDF-1a (Salgia et al., 1999) . Furthermore, BCR-ABL, depending on its level of expression, also diminishes CXCR4 expression at the level of transcription (Geay et al., 2005) . Moreover, the treatment of CML-derived cell lines with BCR-ABL inhibitors increased the expression of CXCR4 and migration to SDF-1a (Jin et al., 2008) . Collectively, the downregulation of CXCR4 by BCR-ABL seems to be a powerful explanation as to why premature myeloid cells migrate away from the bone marrow in CML. In this study we demonstrated that CXCR4 expression was dramatically reduced when both STAP-2 and BCR-ABL were simultaneously transfected into Ba/F3 cells, which express neither STAP2 nor BCR-ABL. In K562 cells, which express both STAP-2 and BCR-ABL, CXCR4 expression was greatly enhanced by the inhibition of STAP-2. Thus, our data suggest a strong involvement of STAP-2 in the linkage of BCR-ABL and CXCR4. Coupled with our previous results indicating that STAP-2 enhances SDF-1a signaling through interactions with Vav (Sekine et al., 2009a) , STAP-2 is likely to regulate SDF-1a/CXCR4 at multiple levels in CML cells. Therefore, STAP-2 is likely to play a crucial role in the pathogenesis of CML.
The differences in tumor progression observed between BCR-ABL and BCR-ABL/STAP-2-expressing Ba/F3 cells represent an attractive target for the development of therapies for CML. A massive infiltration of tumor cells into the lymph nodes, spleen and liver was observed when Ba/F3 cells expressing BCR-ABL/ STAP-2, but not BCR-ABL, were implanted into mice. Our data regarding chemokine receptors may explain this difference. In addition to CXCR4 expression, STAP-2 may interact with BCR-ABL to upregulate CCR1 and CCR7 expression. Because CCR7 interacts with secondary lymphoid tissue chemokines such as CCL19 and CCL21 (Mburu et al., 2006) , such a change of chemokine receptor expression may in part explain the different invasiveness. It would be of interest to determine whether the chemokine receptor expression profile, depending on STAP-2 expression, may be related to the splenomegaly observed in CML patients.
In summary, this study provides evidence that STAP-2 is significantly involved in BCR-ABL activation and that STAP-2 expression plays a crucial role in the BCR-ABL-mediated growth advantage, altered chemokine receptor expression and the resistance to imatinib. Therefore, STAP-2 is likely to underlie CML progression and imatinib sensitivity. Collectively, STAP-2 is essential for the complete activation of BCR-ABL in CML cells. Thus, STAP-2 represents a suitable molecular target against which novel strategies to treat CML might be developed and STAP-2 expression has the potential to offer useful insight into the characteristics of individual CML clones.
Materials and methods
Reagents and antibodies
Recombinant human SDF-1a was purchased from PeproTech (London, UK). BCR-ABL tyrosine kinase inhibitor, STI571 (imatinib mesylate), was kindly gifted by Novartis Pharmaceuticals (Basel, Switzerland). Expression vectors for p190/ p210BCR-ABL, ABL, STAP-2 and their mutants were described previously Toyofuku et al., 2004; Sekine et al., 2005; Tokunaga et al., 2010) . Expression vectors for Myc-tagged-BCR was generated by PCR methods and sequenced (primer sequences are available upon request). Anti-ABL anti-BCL-2, anti-BCL-xL and antiphospho ERK (pERK) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Myc, anti-GST, anti-actin monoclonal antibody and anti-PY monoclonal antibody (PY20) were purchased from Sigma-Aldrich (St Louis, MO, USA). Anti-ERK antibody was purchased from Cell Signaling Technologies (Beverly, MA, USA). Anti-VAV antibody was purchased from Millipore (Billerica, MA, USA). Anti-CBL antibody was purchased from Epitomics, Inc. (Burlingame, CA, USA). Anti-STAP-2 antibody was purchased from Everest Biotech (Oxfordshire, UK).
